Scarica l'app Stockscreener
1.98
21.12%
-0.53
Precedente Chiudi:
$2.51
Aprire:
$2.5
Volume 24 ore:
530.45K
Relative Volume:
0.34
Capitalizzazione di mercato:
$24.97M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-36.54%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$1.925
$2.55
Intervallo di 1 settimana:
$1.925
$3.24
Portata 52W:
$1.925
$9.36
Propanc Biopharma Inc Stock (PPCB) Company Profile
Nome
Propanc Biopharma Inc
Settore
Industria
Telefono
61-03-9882-0780
Indirizzo
302/6 BUTLER STREET, CAMBERWELL, VICTORIA
Confronta PPCB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PPCB
Propanc Biopharma Inc
|
2.87 | 244.39K | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
1.40 | 2.19B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.45 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.41 | 111.01M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.3762 | 672.88M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.1699 | 0 | 0 | 0 | 0 | 0.00 |
Propanc Biopharma Inc Borsa (PPCB) Ultime notizie
Propanc Biopharma announces plan to acquire $100 million of Ethereum - MSN
Propanc Biopharma’s $100M Ethereum Allocation: A Strategic Gamble or a Path to Growth? - AInvest
Propanc Biopharma, Inc. Announces $100 Million Ethereum Acquisition Plan to Enhance Growth and Diversification Strategy - Quiver Quantitative
Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum - The Manila Times
$100M Ethereum Investment: Cancer Drug Developer Propanc Makes Bold Move into Crypto for Growth Strategy - Stock Titan
Propanc Biopharma Secures $4 Million in Public Offering to Advance Cancer Stem Cell Research - citybuzz -
D. Boral Capital Leads Propanc Biopharma's $4,000,000 Uplisting on Nasdaq - AInvest
D. Boral Capital Acted as Lead Bookrunner to Propanc Biopharma, Inc. (Nasdaq:PPCB) in Connection with its $4,000,000 Uplisting - Newswire.com
Propanc Biopharma raises $4 million in Nasdaq debut, plans cancer trials - Investing.com
Propanc Biopharma shares fall 3.26% after-hours following shareholder update on corporate developments and Phase 1B study. - AInvest
Propanc Biopharma provides shareholder update - MarketScreener
Propanc Biopharma prepares for phase 1B cancer drug trial in 2026 By Investing.com - Investing.com South Africa
Propanc Biopharma prepares for phase 1B cancer drug trial in 2026 - Investing.com Nigeria
Propanc Biopharma Provides Shareholder Update - The Manila Times
Propanc Biopharma Announces Shareholder Update and 2025/26 Forecast. - AInvest
Propanc Biopharma: Recent IPO and Up-listing to Nasdaq, Advancing Lead Asset to Phase 1B Study - AInvest
$18.1B Market Potential: Propanc's Novel Cancer Drug PRP Heads to Human Trials After Successful Nasdaq IPO - Stock Titan
Propanc Biopharma Completes Public Offering on Nasdaq - MSN
Propanc Biopharma opens at $4.00 in Nasdaq uplisting - MSN
Biotech’s Big Bang: IPOs, Uplists, and the Short Squeeze Effect - The Globe and Mail
PPCB: Is Recent Nasdaq Uplisting a Game-Changer? - StocksToTrade
Propanc Biopharma’s Surging Market Debut: What’s Next? - timothysykes.com
Stocks Moving Premarket: NBY, AUDD, PPCB And Other Gainers & Losers - RTTNews
Propanc Biopharma shares rise 34.88% premarket after closing a $4 million public offering. - AInvest
Propanc Biopharma closes public offering, uplists to NASDAQ - MSN
Propanc Biopharma Stock Soars 51.23% on Capital Raise - AInvest
Propanc Biopharma shares rise 61.58% premarket after closing a $4 million public offering. - AInvest
Why Did Propanc Biopharma Stock Soar 27.25%? - AInvest
The Most Effective Trade Strategy Right Now - timothysykes.com
Propanc Biopharma Announces Nasdaq Uplisting, $4M Public Offering - AInvest
Propanc Biopharma shares rise 19.89% after-hours after closing a $4 million public offering. - AInvest
Propanc Biopharma shares rise 21.20% after-hours after closing a $4 million public offering. - AInvest
Propanc Biopharma Raises $4M Through Public Offering, Begins Trading on NASDAQ - AInvest
Propanc Biopharma's NASDAQ Uplisting: A Strategic Leap in Immuno-Oncology's High-Stakes Arena - AInvest
Propanc Biopharma closes $4 million public offering, lists on Nasdaq - Investing.com
Propanc Biopharma closes $4 million public offering, lists on Nasdaq By Investing.com - Investing.com UK
Propanc Biopharma raises $4 million in underwritten public offering. - AInvest
Propanc Biopharma Completes Public Offering, Uplisted to NASDAQ - AInvest
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ - MarketScreener
Cancer Treatment Developer Propanc Biopharma Raises $4M in IPO, Achieves Major Nasdaq Uplisting Milestone - Stock Titan
Propanc Biopharma Plunges 15.04% Amid Tariff Fears - AInvest
Why Propanc stock Is Tumbling In Premarket Today - Asianet Newsable
Precipio Announces Second Quarter 2022 Results, Revenue Up 18% YoY - AInvest
Propanc Biopharma prices $4M stock offering - MSN
Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August - inkl
PPCB Stock Quote - richtv.io
Propanc Biopharma Uplisting: What Lies Ahead? - timothysykes.com
Propanc Biopharma Stock (PPCB) Surges 150% After Nasdaq Uplisting and Public Offering. - AInvest
Stocks Moving Premarket: PPCB, BTAI, TNXP, DAY, TPIC, and Other Gainers & Losers - AInvest
PPCB Stock Price and Chart — NASDAQ:PPCB - TradingView
Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering - The Manila Times
Propanc Biopharma Inc Azioni (PPCB) Dati Finanziari
Non sono disponibili dati finanziari per Propanc Biopharma Inc (PPCB). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):